mitoxantrone, 11, 12 busulfan 11, 14, 15 or melphalan, 11, [13] [14] [15] have shown activity in lymphoma patients with or without CNS involvement. To our knowledge, there are no reports of the specific combination of thiotepa, etoposide and cyclophosphamide (VP/Cy/TT) as a conditioning regimen for NHLs. Here we report the long-term outcomes with this conditioning regimen for auto-HCT in patients with NHL.
This single center retrospective study was approved by the Institutional Review Board at West Virginia University. Consecutive adult (age 18 years or older) NHL patients undergoing auto-HCT after conditioning with VP/Cy/TT were eligible for this study between 1997 and 2009. The conditioning regimen consisted of etoposide (1800 mg/m 2 IV over 27 h) on day − 10, thiotepa (300 mg/m 2 IV) on days − 8 to − 6 and cyclophosphamide (50 mg/kg IV) on days − 5 to − 2. In June 2002, after the first 10 patients, the regimen was changed to etoposide (1800 mg/m 2 IV over 27 h) on day − 7, thiotepa (250 mg/m 2 IV) every morning on days − 5 to − 2 and cyclosphosphamide (50 mg/kg IV) every evening on days − 5 to − 2. PBSC were mobilized using cyclophosphamide and filgastrim. All patients in the revised regimen after June 2002 received filgrastim support post transplant along with prophylactic levofloxacin, acyclovir and fluconazole. Transfusion support and management of febrile neutropenia were provided per institutional protocol.
CR was defined as the resolution of all disease by imaging or biopsy when indicated. PR was defined as a reduction of tumor burden by at least 50%. Engraftment was defined as the first of 3 consecutive days with an ANC4500 cells/mm 3 . Platelet recovery was defined as the first of 7 consecutive days with the platelet count 420 000/mm 3 without a platelet transfusion. PFS was calculated using the Kaplan-Meier method from the date of transplant to the date of disease relapse/progression or death from any cause. Overall survival was calculated using the Kaplan-Meier method from the date of transplant to death from any cause. Patients who did not experience the respective events were censored at the date of last follow-up. A total of 42 consecutive adult patients with NHL who underwent auto-HCT between November 1997 and May 2009 with VP/CY/TT conditioning were included. Table 1 outlines patient characteristics before transplantation. Diffuse large B-cell lymphoma was the most common diagnosis accounting for 57% (n = 24) of cases followed by follicular lymphoma at 17% (n = 7). Advanced stage disease (Ann Arbor stage III/IV ) was noted in 52% (n = 22). Two patients did not have staging information available. International Prognostic Index scores were used for prognostic markers and were divided into low (0-1), intermediate (2) (3) and high (4) (5) . The majority of these patients (n = 23, 55%) had intermediate risk International Prognostic Index.
Median follow-up for surviving patients was 6.1 years (range 0.4-17.8 years). Median time to neutrophil and platelet engraftment was 13 (range 10-25) and 21 (range 7-204) days, respectively. Significant regimen-related toxicities included mucositis (52%), neutropenic fever (74%), diarrhea (26%) and pneumonia (7%). Seventeen patients (40%) developed grade 3-4 mucositis. Secondary malignancies occurred in four patients (10%)-two of which were soft tissue sarcomas, one squamous cell carcinoma of the tongue and one myelodysplastic syndrome (MDS)/AML. There were no reports of late onset pulmonary or cardiac toxicities in surviving patients. PFS and overall survival at 5 years was 53% (95% CI: 39-71%) and 73% (95 CI: 60-89%), respectively ( Figure 1) . Relapse rates at day +100 and 5 years were 9% (95% CI: 3-20%) and 40% (95% CI: 25-55%), respectively. Cumulative incidence of NRM at day +100 and 5 years was 2% (95% CI: 0.4-12%) and 7% (95% CI: 2-17%), respectively. Cause of death for NRM was infection/sepsis in all cases. No patients experienced CNS relapse post transplant, including the two patients with prior CNS involvement by lymphoma.
Our study evaluating the long-term post-transplant outcomes with VP/Cy/TT preparative regimen in NHL patients is noteworthy. The regimen was well tolerated with prompt hematopoietic recovery and favorable NRM. As expected, lymphoma relapse/ progression was the primary cause of treatment failure. Survival outcomes (PFS and OS) at 5 years are encouraging. Although there were four cases (10%) of secondary malignancies, no other long-term end-organ toxicities were noted. CNS disease was too infrequent to infer conclusions on efficacy in this patient subset. In summary, VP/Cy/TT is a safe and feasible high-dose conditioning regimen before auto-HCT in NHL patients and prospective studies are warranted to evaluate this regimen further. 
